September 17, 2024 01:00 AM EDTUpdated 06:31 AM

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Kyle LaHucik

Senior Reporter

BARCELONA — A month after gutting its internal drug discovery group, 23andMe is trudging along with the experimental medicines it’s already brought …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Breaking down silos with a new quantitative approach to drug development

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team